Contactez-nous
Catalogue de Produits
Available products for licensing and manufacturing — finished dosage forms (FDF), APIs and intermediates.

Catalogue de Produits

Filter by product line. Listings without a line tag appear under "All".

Search in table

100 of 100 products

Product | Strength | Dosage form
Market
Offer type
Contact
Injectables for early phase clinical trials https://eramol.com/clinical-services/sterile-manufacturing/aseptic/
Global
Supply, Marketing Authorization (MA), Tech transfer, Dossier
Linaclotide (CAS: 851199-59-2)
Nifédipine (CAS: 21829-25-4)
Azithromycine
Mexico
Dossier
Érythromycine
CIS countries
Dossier
Isosorbide Mononitrate (Diluted with Lactose) (USP/IP/Ph. Eur) - 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% (CAS: 16051-77-7)
Paracétamol, solution pour perfusion, 10 mg/ml, 100 ml dans un flacon
European Union (EU)
Dossier
Rivaroxaban, comprimés pelliculés, 2,5 mg, 10 mg, 15 mg, 20 mg
European Union (EU)
Dossier
Desloratadine, sirop, 0,5 mg/ml
European Union (EU)
Dossier
Drotavérine, solution injectable, 20 mg/ml, 2 ml dans une ampoule
European Union (EU)
Dossier
Dexaméthasone, solution injectable, 4 mg/ml, 1 ml dans une ampoule
European Union (EU)
Dossier
Moxifloxacine Hydrochlorure, solution pour perfusion, 400 mg, 250 ml dans un flacon
European Union (EU)
Dossier
Metronidazole, solution pour perfusion, 5 mg/ml, 100 ml dans un flacon
European Union (EU)
Dossier
Chlorure de sodium, solution pour perfusion 100 ml, 200 ml, 250 ml, 400 ml, 500 ml dans un flacon
European Union (EU)
Dossier
Fluconazole, solution pour perfusion, 2 mg/ml, 100 ml dans une bouteille
European Union (EU)
Dossier
Sorbitol, chlorure de sodium, chlorure de potassium, dihydraté de chlorure de calcium, hexahydraté de chlorure de magnésium, lactate de sodium, solution pour perfusion de 200 ml dans une bouteille
European Union (EU)
Dossier
Sulfate de magnésium, solution injectable, 250 mg/ml
European Union (EU)
Dossier
Benzidamine Hydrochloride, spray buccal, 1,5 mg/ml, 3,0 mg/ml
European Union (EU)
Dossier
Benzidamine Hydrochloride, solution orale, 1,5 mg/ml
European Union (EU)
Dossier
Xylométazoline, spray nasal à dose mesurée, 1,0 mg/ml, 0,5 mg/ml
European Union (EU)
Dossier
Chlorure de dequalinium, chlorhydrate de cinchocaïne, pastilles
European Union (EU)
Dossier
Doxylamine, gouttes orales, 15 mg/0,6 ml
European Union (EU)
Dossier
Doxylamine, comprimés enrobés, 15 mg
European Union (EU)
Dossier
Dexmédétomidine hydrochlorure, concentré pour solution pour perfusion, 100 m g/ml
European Union (EU)
Dossier
Atracurium besylate, solution injectable, 10 mg/ml
European Union (EU)
Dossier
Meloxicam, comprimés, 7,5 mg, 15 mg
European Union (EU)
Dossier
Meloxicam, solution injectable, 15 mg
European Union (EU)
Dossier
Etoricoxib, comprimés pelliculés, 60 mg, 90 mg, 120 mg
European Union (EU)
Dossier
Dexkétoprofène, solution injectable, 50 mg/2 ml
European Union (EU)
Dossier
Ibuprofène, lévométhol, gel, 50 mg/30 mg
European Union (EU)
Dossier
Ibuprofène, comprimés pelliculés, 200 mg, 400 mg
European Union (EU)
Dossier
Valsartan, comprimés pelliculés, 80 mg, 160 mg
European Union (EU)
Dossier
Furosémide, solution injectable, 10 mg/ml
European Union (EU)
Dossier
Tablettes de périndopril, indapamide, amlodipine, 4 mg/1,25 mg/5 mg ; 4 mg/1,25 mg/10 mg ; 8 mg/2,5 mg/5 mg ; 8 mg/2,5 mg/10 mg
European Union (EU)
Dossier
Tablettes de lisinopril 10 mg, 20 mg
European Union (EU)
Asset sale
Comprimés pelliculés d'éplérénone, 25 mg, 50 mg
European Union (EU)
Asset sale
Perindopril, comprimés d'indapamide, 4 mg/1,25 mg, 8 mg/2,5 mg
European Union (EU)
Dossier
Comprimés pelliculés d'acide acétylsalicylique, 75 mg, 150 mg
MENA, APAC, CIS
Asset sale
Oral solid dose for clinical trials https://eramol.com/clinical-services-category/non-sterile-manufacturing/
Global
Supply, Dossier, Marketing Authorization (MA), Tech transfer
Insulin (CAS: 11061-68-0)
ANTICOAGULANT SODIUM CITRATE 4% 250 ml
North America (USA, Canada, Mexico)
Supply
D-Pantothénate de calcium (CAS: 137-08-6)
Tablettes de nitrendipine 10 mg (CAS: 39562-70-4)
Isosorbide Dinitrate (Diluted with Lactose) (USP/IP/ Ph. Eur) - 40% (CAS: 87-33-2)
Urapidil Hydrochloride 30mg Préparations orales (CAS: 64887-14-5)
10-Methoxy Iminostilbene (CAS No: 4698-11-7) (CAS: 4698-11-7)
Erythromycin Ethyl Succinate (CAS: 1264-62-6)
Comprimés de finérone 10 mg (CAS: 1050477-31-0)
2-Cyano phenothiazine (CAS No: 38642-74-9) (CAS: 38642-74-9)
Erythromycin Estolate (CAS: 3521-62-8)
Sitagliptine Phosphate Monohydraté 25 mg Comprimés Pelliculés (CAS: 654671-77-9)
Cypionic Acid (3-Cyclopentylpropionic Acid) (CAS No: 140-77-2) (CAS: 140-77-2)
2-acetyl-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (CAS: 1095825-46-9)
Erythromycin Stearate (CAS: 643-22-1)
Empagliflozine 10 mg Comprimés pelliculés (CAS: 864070-43-9)
Tablettes de Glimepiride 1 mg (CAS: 93479-97-1)
Difluoro-bromo-Aniline (CAS No: 67567-26-4) (CAS: 4698-11-7)
F-moc Osu (CAS: 82911-69-1)
Comprimés pelliculés de calcium de pitavastatine 1 mg (CAS: 147526-32-7)
Fmoc-Trp(N-CH2COOAll)-OH (CAS: 2883650-94-8)
Capsules de Clofibrate 100mg (CAS: 637-07-0)
Fmoc-Asp(OMpe)-OH (CAS: 180675-08-5)
Tablettes de Diclofénac Sodique 25mg (CAS: 15307-79-6)
Fmoc-Ser(tBu)-Ser[Psi(Me,Me)Pro]-OH (CAS: 1000164-43-1)
Tablettes pelliculées de Febuxostat 20 mg (CAS: 144060-53-7)
Capsules de célecoxib 50 mg (CAS: 169590-42-5)
9-Fluorenyl methanol (CAS No: 24324-17-2) (CAS: 24324-17-2)
Trimebutine maleate (CAS: 34140-59-5)
Acétylsalicylate de lysine (Non stérile/Stérile) Comprimés de 100 mg (CAS: 62952-06-1)
Tablettes de Gastrodin 25 mg (CAS: 62499-27-8)
Cyclopentylpropionyl Chloride (CAS No: 104-97-2) (CAS: 104-97-2)
Salcaprozate sodium - SNAC (CAS: 203787-91-1)
Tablettes d'antipyrine 270 mg (CAS: 60-80-0)
Tofacitinib Citrate 5mg Comprimés (CAS: 540737-29-9)
7-Ethyl tryptophol (CAS No: 41340-36-7) (CAS: 41340-36-7)
5-butyl-1H-benzotriazole (CAS: 3663-24-9)
Comprimés de Benorilate 500 mg (CAS: 5003-48-5)
Injection de Sodium Avibactam 2g (CAS: 1192491-61-4)
Dimethyl Isosorbide (CAS No: 5306-85-4) (CAS: 5306-85-4)
Tablettes de voriconazole 50 mg (CAS: 137234-62-9)
Tablettes de nicotinylméthylamide 500 mg (CAS: 3569-99-1)
Tablettes de Potassium Diclofénac 12,5 mg (CAS: 15307-81-0)
Tablettes d'aceclofénac 50 mg (CAS: 89796-99-6)
Tablettes d'indobufène 200 mg (CAS: 63610-08-2)
Tablettes d'Hydrochlorure d'Ambroxol 30 mg (CAS: 23828-92-4)
Tablettes de chlorure d'ammonium 300 mg (CAS: 12125-02-9)
Tablettes de fumarate de vonoprazan 10 mg (CAS: 2127152-98-9)
Tablettes de Pantoprazole Sodique 20 mg (CAS: 164579-32-2)
Tablettes de Dihydroxyaluminium Aminoacétate 250 mg (CAS: 41354-48-7)
Tablettes à libération prolongée de Rabéprazole Sodique 10 mg (CAS: 117976-90-6)
Injection de sodium d'ésoméprazole 40 mg (CAS: 119141-88-7)
Glycine 100mg Comprimés sublinguaux (CAS: 56-40-6)
L-Lysine Hydrochloride 100mg Comprimés (CAS: 10098-89-2)
Tablettes de phenprobamate 200 mg (CAS: 63-91-2)
Injection d'aceglutamide 100 mg (CAS: 2490-97-3)
Comprimés de vitamine E 5 mg (CAS: 2074-53-5)
Tablettes d'acétoménadione 2 mg (CAS: 546-88-3)
Injection de sulfate de gentamicine 40 mg (CAS: 1405-41-0)
Tablettes d'oxytétracycline 125 mg (CAS: 79-57-2)
Comprimés de chlorhydrate de lincomycine 250 mg (CAS: 859-18-7)

Explore pharma products for licensing and distribution

The demand for pharma products for licensing continues to grow as companies seek faster ways to expand portfolios, secure distribution rights, and accelerate entry into regulated markets. MAI CDMO Network offers a searchable pharmaceutical product list where every record includes the essential fields: product name, strength, dosage form, market, and offer type. This structure allows portfolio managers, distributors, and business development teams to easily find opportunities for in-licensing, MA/MAH licensing, dossier licensing, and CDMO manufacturing.

Searchable product data

The system is designed to give buyers clear and actionable information: ⬢ Product name + strength + dosage form: for example, "Amoxicillin 500 mg tablets" or "Atorvastatin 20 mg capsules." ⬢ Market: a dropdown selector covering global regions and key countries. ⬢ Offer type: choose whether the listing is manufacturing only, distribution rights only, marketing authorization (MA), or combinations such as MA + Manufacturing and MA + Distribution rights.

Markets covered in detail

Licensing opportunities are not limited to one geography. MAI CDMO Network covers a broad spectrum of territories, allowing users to filter by region or key country: ⬢ Global: products available for worldwide licensing and distribution. ⬢ European Union (EU): suitable for centralized or decentralized EMA submissions. ⬢ European Economic Area (EEA): extending coverage beyond the EU to additional European markets. ⬢ North America (USA, Canada, Mexico): includes FDA and Health Canada compliant dossiers and distribution opportunities. ⬢ Latin America (LATAM): markets like Brazil, Argentina, and Mexico with growing demand for generic drugs for licensing. ⬢ Middle East & North Africa (MENA): regional authorizations and distribution rights adapted to local agencies. ⬢ Sub-Saharan Africa: diverse opportunities for essential medicines and ready-to-license pharmaceuticals. ⬢ Asia-Pacific (APAC): fast-growing markets such as China, India, Japan, and Australia. ⬢ CIS countries: including Russia and neighboring markets with specific regulatory frameworks. Key individual markets are also listed for more precise targeting: United States, Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Italy, Spain, China, India, Japan, and Australia. This granularity makes it possible to match pharmaceutical licensing opportunities to your exact territory needs.

Types of offers available

Each listing specifies the offer type so you can identify what is on the table: ⬢ Manufacturing only: contract manufacturing without licensing or distribution rights. ⬢ Distribution rights only: commercial rights to sell in defined territories. ⬢ Marketing Authorisation (MA): access to an existing MA or the ability to license it. ⬢ Manufacturing + Distribution rights: supply plus sales authorization in chosen markets. ⬢ MA + Manufacturing: licensing of the authorization combined with production rights. ⬢ MA + Manufacturing + Distribution rights: a complete package including regulatory, supply, and commercialization. This transparent categorization helps companies quickly evaluate whether a product is aligned with their business model, whether that means sourcing from a CDMO, obtaining distribution rights, or acquiring marketing authorization licensing.

Benefits for different users

The MAI CDMO Network licensing catalog is designed for: ⬢ Pharma companies: to expand their pipeline with in-licensed assets and accelerate market entry. ⬢ Distributors: to secure distribution rights in their regions with minimal lead time. ⬢ CDMOs and manufacturers: to showcase products where they can provide manufacturing services. ⬢ Startups and smaller firms: to use dossier licensing plus CDMO manufacturing for quick launches.

Why use MAI CDMO Network

By consolidating pharma products for licensing into one searchable database, MAI CDMO Network reduces the time and complexity of identifying new opportunities. The structure � product name, strength, dosage form, market, and offer type � provides clarity and comparability. Whether you are seeking MA/MAH licensing, dossier licensing, or distribution rights, the platform makes it simple to find, filter, and connect with the right partner. With global coverage spanning EU, EEA, North America, LATAM, MENA, Sub-Saharan Africa, APAC, CIS, and key countries such as US, UK, Germany, China, India, Japan and more, this catalog is your gateway to ready-to-license pharmaceuticals worldwide.

Get started today

Use MAI CDMO Network to search for pharma products for licensing by product name, strength, dosage form, target market, and offer type. Explore opportunities across EMA, FDA and other regulatory territories, and find the right mix of manufacturing, distribution rights, and MA/MAH licensing to expand your business.
Logo Background

Join the Pharmaceutical Collaboration Ecosystem

More than 15,000 manufacturing plants are already part of the most advanced network in the sector. Don't get left behind.

+50 new leads this month